Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-1716
- Development stage
- Phase 2
- Lead developer
- Virttu Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous, Intrapleural
01
Overview
HSV-1716 is a replication-restricted oncolytic herpes simplex virus developed as a cancer therapeutic. It contains a deletion of the ICP34.5 gene, which is a neurovirulence gene that enables viral replication in neurons. This deletion provides tumor-selective replication properties, allowing the virus to replicate in and kill cancer cells while largely preventing replication in normal cells. The virus works by exploiting the weaker PKR-linked defenses in tumor cells compared to healthy differentiated cells. HSV-1716 has been studied via intratumoral injection, intravenous administration, and intrapleural delivery in various cancer types including glioma, mesothelioma, melanoma, and solid tumors in both adult and pediatric patients[1][2][4][7].
- Brand names
- Seprehvir
- Other names
- Herpes simplex virus 1716
02
Targets
3-O-sulfated heparan sulfateTNFRSF14 (Tumor necrosis factor receptor superfamily member 14)NECTIN1 (Poliovirus receptor-related 1)
Beyond the preview
Go deeper on HSV-1716.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-1716.